Autologous stem cell therapy - Shire

Drug Profile

Autologous stem cell therapy - Shire

Alternative Names: Adult stem cell therapy for chronic myocardial ischaemia - Shire

Latest Information Update: 15 Jun 2016

Price : $50

At a glance

  • Originator Baxter Healthcare Corporation
  • Developer Baxter Healthcare Corporation; Northwestern University; Shire
  • Class Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Myocardial ischaemia
  • No development reported Peripheral vascular disorders

Most Recent Events

  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 11 Aug 2015 No recent reports on development identified - Phase-I/II for Peripheral vascular disorders (critical limb ischaemia) in USA (IM)
  • 11 Aug 2015 The phase III RENEW trial in Myocardial ischaemia is ongoing in USA (NCT01508910)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top